FBXO9 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, when compared to healthy bone marrow (HBM), CML, and myelodysplastic syndrome (MDS), FBXO9 showed decreased expression (Figure 1A and Figure S1A).